Genetic Testing for Hereditary Cancers Can Help Reduce the Risk of Cancer
By detecting cancer early, your patient will have access to preventative measures and proactive treatment – leading to an overall better prognosis.
Genetic Diagnosis of Hereditary Cancer
Testing for hereditary cancers can detect specific, heritable, disease-related gene mutations that may increase the risk of certain cancers allowing an in-depth cancer risk assessment for each patient.
The critical goal is to detect cancer early and to give you the opportunity to maximize health outcomes for your patients. Patient-tailored screening programs, preventive measures and proactive treatment are possible for patients of a high-risk group. Early diagnosis can mean a better overall prognosis through a choice of surgical and non-surgical treatment options.
Hereditary Cancer Feature List
Excellent analysis using the most advanced NGS technology
Includes detection of Copy Number Variants (CNVs)
Affordable prices and shortest turnaround times
Highest level of quality/accuracy
CAP and CLIA and ISO certification and accreditation
Breast and Ovarian Cancer
Providing critical information for affected and non-affected individuals
Comprehensive Cancer Panel
CentoCancer® – CENTOGENE's cancer-risk-related panel, for all patients with a positive family history of cancer
Breast and Ovarian Cancer
Breast cancer is one of the most common cancers in the world affecting ~12.5% of women during their lifetime. 5–10% of these patients have a hereditary form.
Mutations in the BRCA1 and BRCA2 genes are the most common hereditary cause. However, other genes such as ATM, BRIP1, CHEK2, PALB2, RAD51, etc. have also been associated with increased risk.
| Gene test | BRCA1/BRCA2 | CentoBreast® |
|---|---|---|
| Gene name | BRCA1, BRCA2 | ABRAXAS1, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, FANCC, MEN1, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PMS1, PMS2, PTEN, RAD50, RAD51C, RAD51D, RECQL, SMARCA4, STK11, TP53, XRCC2 |
| Diseases covered | Breast cancer | Breast cancer, ovarian cancer |
| Turnaround time | 15 business days | 15 business days |
| How to order | Order a test | Order a test |
Comprehensive Cancer Panel
CentoCancer® is a specific and sensitive panel with all known highly penetrant cancer genes. Each gene has been carefully selected based on its risk potential in the development of one of the following cancers: breast, ovarian, colorectal, gastric, bowel, endometrial, pancreatic, melanoma, renal and prostate cancer.
| Gene test | CentoCancer® |
|---|---|
| Genes name | ABRAXAS1, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, DICER1, DIS3L2, EPCAM, FANCC, FH, FLCN, GALNT12, HNF1B, HOXB13, KIT, MC1R, MEN1, MET, MITF, MLH1, MLH3, MRE11, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PMS1, PMS2, POLD1, POLE, POT1, PRSS1, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RECQL, RET, RNF43, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, STK11, TGFBR2, TP53, TSC1, TSC2, VHL, WT1, XRCC2, XRCC3 |
| Diseases covered | Breast, ovarian, colorectal, gastric, bowel, endometrial, pancreatic, melanoma, renal and prostate cancer |
| Turnaround time | 15 business days |
| How to order | Order a test |
Resources
Useful Links
Downloads
Hereditary Cancer Panels – Product Sheet
Genetic testing for an improved prognosis
Scientific Publications
Turning Rare Disease Networks into Knowledge
CENTOGENE’s well-recognized expertise in Gaucher disease (GD) has helped to establish a global network of physicians interested in and aware of this rare metabolic disorder. The fact that CENTOGENE […]
Related Webinars
Niemann-Pick tipo C: Dos genes – muchos cuadros clínicos – un biomarcador unificador
Mira nuestro webinar sobre Niemann-Pick tipo C, un raro trastorno genético progresivo caracterizado por la incapacidad del cuerpo para transportar el colesterol y otras sustancias grasas (lípidos) […]
Niemann-Pick Type C: Two Genes - Many Clinical Pictures - One Unifying Biomarker
Watch our webinar “Niemann-Pick type C: Two Genes – Many Clinical Pictures – One Unifying Biomarker” hosted by Prof. Peter Bauer. Throughout the webinar, he will provide an overview of this rare […]
A Race Against the Clock – Diagnosing Genetic Conditions in Newborns and Children
Up to one third of all babies and children admitted to the intensive care unit (ICU) have a genetic disease. For many of them early identification can make a difference for their immediate and later […]
Get in Touch With Our Customer Support
Our consultation service is available in several languages.
+49 (0) 381 80 113 - 416
Mon. – Fri. 7 a.m. – 6:30 p.m. CET
Sat. 8 a.m. – 12 p.m. CET